NVS
Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 86.37$. Average daily volumn in 3 months 2.29M. Market cap 195.24B
Stock symbol : NVS. Exchange : NYSE. Currency : USD Lastest price : 92.00$. Total volume : 1.66M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Novartis AG (NVS)
Last Price
92.00$Change
0.42Volume
1.66M
| Previous Close | 91.58 |
| Open | 91.78 |
| Day Range | 91.65-92.19 |
| Bid | 91.01 x 800 |
| Ask | 92.41 x 800 |
| Volume | 1.66M |
| Average Volume | 2.29M |
| Market Cap | 195.24B |
| Beta | 0.46 |
| 52 Week Range | 74.09-94.26 |
| Trailing P/E | 29.02 |
| Foward P/E | 12.92 |
| Dividend (Yield %) | 3.79% |
| Ex-Dividend Date | 2023-03-09 |
Financial Details
Organization
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceu... ticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Market Cap:
195.24BRevenue:
51.83BTotal Assets:
117.45BTotal Cash:
7.52B
News about "Novartis AG"
Novartis AG’s (NVS) Stock: A 7.78% Simple Moving Average for the Past 20 Days
Source from : newsheater - 2 days ago
The stock of Novartis AG (NVS) has seen a 10.04% increase in the past week, with a 7.22% gain in the past month, and a -1.03% decrease in the past quarter. The volatility ratio for the week is 1.24%, ...See details»
Novartis Pharma AG: Novartis Entresto receives positive CHMP opinion for pediatric heart failure
Source from : Finanznachrichten - 16 hours ago
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to Pediatric heart failure is an important cause ...See details»
Novartis AG
Source from : Wall Street Journal - 3 days ago
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»
Before You Sell Novartis AG (NYSE: NVS) Shares, Here’sWhat You Need To Know.
Source from : stocksregister - 6 days ago
Novartis AG (NYSE:NVS) shares, rose in value on Friday, 03/24/23, with the stock price up by 1.31% to the previous day’s close as strong demand from buyers drove the stock to $83.59. Actively ...See details»
Novartis AG: Novartis Posts Strong Kisqali Top-Line Data in Large Adjuvant Treatment Setting
Source from : Yahoo Finance - 4 days ago
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment ...See details»
Novartis AG (NVS) Stock: A Study of the Market Performance
Source from : newsheater - 9 days ago
NVS stock has gone down by -0.17%, with a monthly decline of -5.53% and a quarterly plunge of -9.13%. The volatility ratio for the week is 1.28%, and the volatility levels for the last 30 days are ...See details»
Novartis AG (NVS) Stock Rises on Plan to Increase Profit Margin
Source from : TheStreet.com - 1 month ago
TheStreet Ratings team rates NOVARTIS AG as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation: "We rate NOVARTIS AG (NVS) a BUY. This is based on ...See details»
Novartis AG (NYSE:NVS) Q4 2022 Earnings Call Transcript
Source from : Yahoo - 1 month ago
Novartis AG (NYSE:NVS) Q4 2022 Earnings Call Transcript February 1, 2023 Operator: Good morning and good afternoon, and welcome to the Novartis Q4 2022 Results Release Conference Call and Live ...See details»
Novartis AG Common Stock (NVS)
Source from : Nasdaq - 2 years ago
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...See details»
East Hanover Planning Board rejects Novartis’ proposal to subdivide 17 acres of its campus for sale
Source from : New Jersey Hills - 3 days ago
The Land Use Planning Board unanimously voted Thursday, March 23 to deny an application by Novartis to subdivide about 17 acres of its campus at the ...See details»
Breast Cancer Treatment Market Growth Rate or CAGR is Expected 8.6% in the Coming Year 2027 – Novartis International AG, Pfizer Inc., and Sanofi S.A
Source from : Medgadget - 2 days ago
MarkNtel Advisors introduces the most recent edition of the Breast Cancer Treatment Market, which includes an analysis of numerous market growth factors.See details»
Novartis AG (NVS) stock price, news, quote & history – Yahoo Finance
Source from : Yahoo Finance - 6 month ago
Three years ago Novartis’s decision to collaborate with the NHS on rolling out inclisiran, a twice-yearly injectable drug for lowering cholesterol, was announced to fanfare, after the UK’s slow ...See details»
Novartis Pharma AG: Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Source from : Finanznachrichten - 10 days ago
and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»
Novartis AG (NOVN.SW)
Source from : Yahoo Finance - 2 years ago
The top-shelf drugmakers Novartis (NYSE: NVS) and Vertex Pharmaceuticals (NASDAQ: VRTX) are two prime examples. Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture ...See details»